Agile Therapeutics Inc. (NASDAQ:AGRX) has a beta value of 1.04 and has seen 1.03 million shares traded in the last trading session. The company, currently valued at $12.64M, closed the last trade at $0.31 per share which meant it gained $0.01 on the day or 4.72% during that session. The AGRX stock price is -4932.26% off its 52-week high price of $15.60 and 45.16% above the 52-week low of $0.17. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.95 million shares traded. The 3-month trading volume is 910.99K shares.
The consensus among analysts is that Agile Therapeutics Inc. (AGRX) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.23.
Agile Therapeutics Inc. (NASDAQ:AGRX) trade information
Sporting 4.72% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 01/24/23 when the AGRX stock price touched $0.31 or saw a rise of 2.52%. Year-to-date, Agile Therapeutics Inc. shares have moved 36.74%, while the 5-day performance has seen it change 8.08%. Over the past 30 days, the shares of Agile Therapeutics Inc. (NASDAQ:AGRX) have changed 70.46%. Short interest in the company has seen 0.68 million shares shorted with days to cover at 1.16.
Wall Street analysts have a consensus price target for the stock at $2.00, which means that the shares’ value could jump 84.5% from current levels. The projected low price target is $1.00 while the price target rests at a high of $3.00. In that case, then, we find that the current price level is -867.74% off the targeted high while a plunge would see the stock gain -222.58% from current levels.
Agile Therapeutics Inc. (AGRX) estimates and forecasts
Figures show that Agile Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -37.80% over the past 6 months, with this year growth rate of 92.14%, compared to -4.40% for the industry. Revenue growth from the last financial year stood is estimated to be 143.10%.
1 analysts offering their estimates for the company have set an average revenue estimate of $3.08 million for the current quarter. 1 have an estimated revenue figure of $2.63 million for the next quarter concluding in Mar 2023. Year-ago sales stood $1.51 million and $1.76 million respectively for this quarter and the next, and analysts expect sales will grow by 103.40% for the current quarter and 49.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 5.40% over the past 5 years.
Agile Therapeutics Inc. is expected to release its next earnings report between March 28 and April 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Agile Therapeutics Inc. (NASDAQ:AGRX)’s Major holders
Insiders own 7.84% of the company shares, while shares held by institutions stand at 5.72% with a share float percentage of 6.20%. Investors are also buoyed by the number of investors in a company, with Agile Therapeutics Inc. having a total of 33 institutions that hold shares in the company. The top two institutional holders are Perceptive Advisors Llc with over 0.53 million shares worth more than $0.17 million. As of Sep 29, 2022, Perceptive Advisors Llc held 1.31% of shares outstanding.
The other major institutional holder is LPL Financial LLC, with the holding of over 0.41 million shares as of Sep 29, 2022. The firm’s total holdings are worth over $0.13 million and represent 1.01% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. As of Nov 29, 2022, the former fund manager holds about 0.51% shares in the company for having 0.21 million shares of worth $64823.0 while later fund manager owns 29419.0 shares of worth $9131.0 as of Sep 29, 2022, which makes it owner of about 0.07% of company’s outstanding stock.